Small molecule therapeutics targeting essential mediators of inflammation

Halia Therapeutics is focused on addressing chronic inflammation through innovative therapeutic approaches, particularly by targeting the NLRP3 inflammasome. This protein complex plays a crucial role in mediating systemic inflammatory responses, which can lead to various chronic diseases, including neurodegenerative disorders like Alzheimer's and Parkinson's, as well as conditions such as rheumatoid arthritis and obesity. Halia's strategy involves developing allosteric inhibitors that disrupt the activity of the NLRP3 inflammasome, thereby potentially reducing inflammation and its associated health impacts. Their research indicates that by modulating this pathway, they can not only treat existing conditions but also promote overall longevity and quality of life.

In addition to their work on the NLRP3 inflammasome, Halia is also exploring other significant pathways related to chronic diseases. They are developing compounds that target the NEK7 protein, which is involved in the assembly of the NLRP3 inflammasome, and the LRRK2 kinase, which is linked to neurodegenerative diseases. By leveraging their understanding of these molecular mechanisms, Halia aims to create differentiated small molecules that can effectively cross the blood-brain barrier and address both central nervous system and peripheral inflammatory diseases. Their ongoing clinical trials are designed to evaluate the safety and efficacy of these investigational treatments, with the ultimate goal of providing new therapeutic options for patients suffering from serious chronic conditions.

United States

Halia is a clinical-stage biopharmaceutical company discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. 

We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.

Halia Therapeutics

Company Details